Plasma YKL-40 during pregnancy and gestational diabetes mellitus

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Gestational diabetes mellitus (GDM) is characterised by hyperglycaemia during pregnancy. The clinical circumstances involved in the development of GDM leaves the patient at a high risk of the subsequent development of type 2 diabetes. Plasma levels of the inflammation marker YKL-40 are elevated in type 2 diabetes and correlate with fasting plasma glucose levels and insulin resistance in patients with type 2 diabetes. With the present study we aimed to determine if pregnancy (and associated insulin resistance) with or without GDM affects plasma YKL-40 levels. Plasma from women diagnosed with GDM and healthy normal glucose-tolerant pregnant women (non-GDM) was obtained at the third trimester of pregnancy and again 3-4 months following delivery, and levels of YKL-40 and interleukin 6 (IL-6; known to regulate YKL-40) were measured. Plasma YKL-40 levels were similarly low during pregnancy in both groups and increased significantly after delivery, but remained lower in the GDM group compared with the non-GDM group postpartum. In contrast, plasma IL-6 levels were not affected by pregnancy or diagnosis of GDM, Nevertheless, YKL-40 levels were associated with IL-6 levels in the non-GDM group (but not in the GDM group). Pregnancy seems to be associated with a temporary reduction in circulating YKL-40, which increases after delivery, but to a much lesser extent in women with GDM than in non-GDM women.

OriginalsprogEngelsk
TidsskriftJournal of Reproductive Immunology
Vol/bind112
Sider (fra-til)68-72
ISSN0165-0378
DOI
StatusUdgivet - 2015

Bibliografisk note

Funding Information:
The Centre for Physical Activity Research (CFAS) is supported by a grant from Trygfonden . During the study period, the Centre of Inflammation and Metabolism (CIM) was supported by a grant from the Danish National Research Foundation (DNRF55) . The study was further supported by an unrestricted grant from Sawmill owner Jeppe Juhl and Wife Ovita Juhls Memorial Grant, and by unrestricted grants from the Danish Diabetes Association , Aase and Ejnar Danielsen’s foundation and the Novo Nordisk Foundation . CIM is a member of DD2 — the Danish Center for Strategic Research in Type 2 Diabetes (the Danish Council for Strategic Research, grant no. 09-067009 and 09-075724). The Copenhagen Muscle Research Centre (CMRC) is supported by a grant from the Capital Region of Denmark .

Publisher Copyright:
© 2015 Elsevier Ireland Ltd.

ID: 305734510